10.1017/S0022215120000316 15 AshrafizadehM.ZarrabiA.HashemiF.ZabolianA.SalekiH.BagherianM.et al (2020)
To ensure that dangerous levels of ammonia do not return in the future, continue to apply a maintenance dose of RapidBac
Additional information regarding the interests of such participants will be set forth in the proxy statement/prospectus for the proposed business combination when available
These symptoms occurred largely during the dose-escalation period, were transient and mild/moderate in severity, and led to drug discontinuation in up to 7% of participants in each active therapy group
The available abstract does not provide the detail expected from a modern confirmatory ophthalmology trial, including clear randomisation, masking, comparator treatment, complete adverse-event reporting and independently verified outcomes
10.1097/JSM.0b013e31820f8c2f Clin